Skip to content
Sinemet, Stalevo(levodopa)
Corbilta, Dhivy, Duopa, Inbrija, Levodopa/Carbidopa/Entacapone, Numient, Rytary, Sinemet, Stalevo (levodopa) is a small molecule pharmaceutical. Levodopa was first approved as Sinemet on 1982-01-01. It is used to treat parkinson disease in the USA. It has been approved in Europe to treat parkinson disease. It is known to target G-protein coupled receptor 143.
Download report
Favorite
Novartis Pharmaceuticals
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
Trade Name
FDA
EMA
Inbrija (discontinued: Bendopa, Dopar, Larodopa)
Combinations
Dhivy, Duopa, Rytary, Sinemet, Stalevo (generic drugs available since 1992-08-28, discontinued: Carbilev, Parcopa)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Carbidopa
+
Entacapone
+
Levodopa
Tradename
Company
Number
Date
Products
STALEVO 75Orion PharmaN-021485 RX2008-08-29
1 products, RLD
STALEVO 125Orion PharmaN-021485 RX2008-08-29
1 products, RLD
STALEVO 200Orion PharmaN-021485 RX2007-08-02
1 products, RLD, RS
STALEVO 50Orion PharmaN-021485 RX2003-06-11
1 products, RLD, RS
STALEVO 100Orion PharmaN-021485 RX2003-06-11
1 products, RLD
STALEVO 150Orion PharmaN-021485 RX2003-06-11
1 products, RLD
Carbidopa
+
Levodopa
Tradename
Company
Number
Date
Products
DUOPAAbbVieN-203952 RX2015-01-09
1 products, RLD, RS
DHIVYAvion PharmaceuticalsN-214869 RX2021-11-12
1 products, RLD, RS
RYTARYImpax LaboratoriesN-203312 RX2015-01-07
4 products, RLD, RS
SINEMETOrganonN-017555 RX1982-01-01
3 products, RLD
Show 1 discontinued
Levodopa
Tradename
Company
Number
Date
Products
INBRIJAAcorda TherapeuticsN-209184 RX2018-12-21
1 products, RLD, RS
Show 3 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
carbidopa and levodopaANDA2023-04-18
dhivyNew Drug Application2021-11-29
duopaNew Drug Application2020-05-21
inbrijaNew Drug Application2021-01-05
rytaryNew Drug Application2019-12-19
sinemetNew Drug Application2021-06-01
stalevoNew Drug Application2020-05-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
parkinson diseaseEFO_0002508D010300G20
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Carbidopa / Levodopa, Dhivy, Avion Pharms
110335212039-03-28DPU-219, U-3304, U-3305
114396132039-03-28U-3557
Levodopa, Inbrija, Acorda
85458782032-11-16DP
86854422032-11-16DP
89456122032-11-16DP
93932102032-11-16DP
RE437112029-02-03U-2484
71829612024-02-22DP
84042762023-03-19U-2484
85860932023-03-19U-2484
91556992023-03-19DP
Carbidopa / Levodopa, Rytary, Impax Labs Inc
83774742028-12-26DPU-219, U-1645
84549982028-12-26DPU-219, U-1645, U-1646, U-1647, U-1649
85572832028-12-26DPU-219, U-1645
90896072028-12-26DPU-1645, U-1720
90896082028-12-26DP
94632462028-12-26DPU-219
95330462028-12-26DPU-219
99016402028-12-26DPU-219
ATC Codes
N: Nervous system drugs
N04: Anti-parkinson drugs
N04B: Dopaminergic agents
N04BA: Dopa and dopa derivatives
N04BA01: Levodopa
N04BA02: Levodopa and decarboxylase inhibitor
N04BA03: Levodopa, decarboxylase inhibitor and comt inhibitor
HCPCS
Code
Description
J7340
Carbidopa 5 mg/levodopa 20 mg enteral suspension, 100 ml
Clinical
Clinical Trials
249 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Parkinson diseaseD010300EFO_0002508G203550342718155
Healthy volunteers/patients94114
StrokeD020521EFO_0000712I63.9122317
DepressionD003863F33.9415
DyskinesiasD020820G2421115
Back painD001416HP_0003418M54213
Cognitive dysfunctionD060825G31.84123
Post-traumatic stress disordersD013313EFO_0001358F43.1112
Neurologic gait disordersD020233R26.1112
Major depressive disorderD003865EFO_0003761F2222
Show 12 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cocaine-related disordersD019970F1416118
Spinal cord injuriesD013119EFO_10019192213
Angelman syndromeD017204Orphanet_72Q93.5111113
Restless legs syndromeD012148EFO_0004270G25.81213
Orthostatic hypotensionD007024I95.11112
AmblyopiaD000550H53.00112
Stroke rehabilitationD00007193911
Ischemic strokeD00008324211
Broca aphasiaD001039111
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Macular degenerationD008268EFO_0001365H35.3055
Movement disordersD009069EFO_0004280G25213
Central nervous system diseasesD002493HP_0002011G96.922
Brain diseasesD001927HP_0001298G93.4022
Neurodegenerative diseasesD019636EFO_0005772G31.922
Acute painD059787R5222
AlbinismD000417E70.322
SchizophreniaD012559EFO_0000692F20112
Opioid-related disordersD009293EFO_0005611F11112
Parkinsonian disordersD020734HP_0001300112
Show 9 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pure autonomic failureD05497011
PharmacokineticsD01059911
Traumatic brain injuriesD000070642S0611
Consciousness disordersD00324411
Amyotrophic lateral sclerosisD000690EFO_0000253G12.2111
Motor neuron diseaseD016472EFO_0003782G12.211
PlacebosD01091911
SmokingD012907EFO_0003768F1711
AsthmaD001249EFO_0000270J4511
Tourette syndromeD005879EFO_0004895F95.211
Show 2 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple system atrophyD01957822
Sleep wake disordersD012893G4711
Pain thresholdD01728811
AlcoholismD000437EFO_0003829F10.111
Substance-related disordersD019966EFO_0003890F1311
Essential tremorD020329EFO_0003108G25.011
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLEVODOPA
INNlevodopa
Description
L-dopa is an optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease It has a role as a prodrug, a hapten, a neurotoxin, an antiparkinson drug, a dopaminergic agent, an antidyskinesia agent, an allelochemical, a plant growth retardant, a human metabolite, a mouse metabolite and a plant metabolite. It is a dopa, a L-tyrosine derivative and a non-proteinogenic L-alpha-amino acid. It is a conjugate acid of a L-dopa(1-). It is an enantiomer of a D-dopa. It is a tautomer of a L-dopa zwitterion.
Classification
Small molecule
Drug classdopamine receptor agonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O
Identifiers
PDB6ON3
CAS-ID59-92-7
RxCUI6375
ChEMBL IDCHEMBL1009
ChEBI ID15765
PubChem CID6047
DrugBankDB01235
UNII ID46627O600J (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
GPR143
GPR143
Organism
Homo sapiens
Gene name
GPR143
Gene synonyms
OA1
NCBI Gene ID
Protein name
G-protein coupled receptor 143
Protein synonyms
ocular albinism 1, Ocular albinism type 1 protein
Uniprot ID
Mouse ortholog
Gpr143 (18241)
G-protein coupled receptor 143 (P70259)
Variants
Clinical Variant
No data
Financial
Sinemet - Organon
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Rytary - Amneal Pharmaceuticals
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Inbrija - Acorda Therapeutics
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 27,884 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
577 adverse events reported
View more details